Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics
29 Giugno 2020 - 11:34PM
Business Wire
Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a
special purpose acquisition company sponsored by Perceptive
Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a
clinical-stage biopharmaceutical company active in the discovery
and development of T cell redirecting cancer immunotherapies, today
announced that its respective shareholders approved the business
combination between Arya and Immatics announced on March 17, 2020.
None of Arya’s shareholders redeemed their shares in connection
with the ARYA shareholder approval. The respective boards of
directors of both Arya and Immatics had previously approved the
business combination.
Following the Arya shareholder vote, Immatics and Arya commenced
final procedures towards the closing of the business combination
and expect the closing to be completed in the coming days. It is
further expected that the trading of the shares of the combined
company, called Immatics N.V., will commence under the symbol
“IMTX” on the first trading day thereafter. Immatics will continue
to operate under its existing management team led by Chief
Executive Officer, Harpreet Singh, Ph.D.
About the Transaction On March 17, 2020, Immatics entered
into a definite business combination agreement with Arya and in
connection with the entry into the business combination agreement,
a group of leading U.S. healthcare institutional investors
committed to invest in Immatics N.V. through an ordinary share
private investment in public equity (“PIPE”). Immatics
shareholders, Arya shareholders and the PIPE investors will hold
shares in Immatics N.V.
Advisors Goldman Sachs International is acting as lead
financial advisor with SVB Leerink, BofA Securities and Kempen
serving as financial advisors to Immatics. Jefferies LLC is acting
as lead financial and capital markets advisor to Arya as well as
sole private placement agent. Chardan Capital Markets LLC is also
serving as advisor to Arya. Goodwin Procter LLP and CMS Legal
Services EEIG are acting as legal counsel to Immatics. Kirkland
& Ellis LLP is serving as legal counsel to Arya.
About Immatics Immatics combines the discovery of true
targets for cancer immunotherapies with the development of the
right T cell receptors with the goal of enabling a robust and
specific T cell response against these targets. This deep know-how
is the foundation for our pipeline of Adoptive Cell Therapies and
TCR Bispecifics as well as our partnerships with global leaders in
the pharmaceutical industry. We are committed to delivering the
power of T cells and to unlocking new avenues for patients in their
fight against cancer.
For regular updates about Immatics, visit www.immatics.com. You
can also follow us on Twitter and LinkedIn.
About Arya Arya is a blank check company incorporated as
a Cayman Islands exempted company for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more
businesses or entities.
Forward-Looking Statements Certain statements in this
press release may be considered forward-looking statements.
Forward-looking statements generally relate to future events or
Immatics’ future financial or operating performance. For example,
statements concerning the timing of product candidates and
Immatics’ focus on partnerships to advance its strategy are
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as “may”, “should”,
“expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these
terms or variations of them or similar terminology. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by Immatics and its
management, are inherently uncertain. New risks and uncertainties
may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Factors that may cause actual results to
differ materially from current expectations include, but are not
limited to, various factors beyond management's control including
general economic conditions and other risks, uncertainties and
factors set forth in filings with the Securities and Exchange
Commission (SEC). Nothing in this presentation should be regarded
as a representation by any person that the forward-looking
statements set forth herein will be achieved or that any of the
contemplated results of such forward-looking statements will be
achieved. You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Immatics
undertakes no duty to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200629005747/en/
For Media Enquiries Gretchen Schweitzer or Jacob
Verghese, PhD Trophic Communications Phone: +49 89 2388 7731
immatics@trophic.eu Investor Relations Contact John Graziano
Solebury Trout Phone: +1 646-378-2942 jgraziano@soleburytrout.com
Immatics N.V. Anja Heuer Corporate Communications Phone: +49
89 540415-606 media@immatics.com Jordan Silverstein Head of
Strategy Phone: +1 281-810-7545 InvestorRelations@immatics.com
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni ARYA Sciences Acquistion... (NASDAQ:ARYA)
Storico
Da Giu 2023 a Giu 2024